.NET Authors: Tad Anderson, Ivan Antsipau, Liz McMillan, Pat Romanski, Matt Hester

News Feed Item

Merus Labs International Inc. Notified of a Canadian ANDS Filing

TORONTO, ONTARIO -- (Marketwired) -- 06/03/14 -- Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL)(NASDAQ: MSLI) has been notified that Apotex Inc. has filed with Health Canada an Abbreviated New Drug Submission ("ANDS") seeking market approval for a generic version of Enablex® (darifenacin hydrobromide tablets) for the Canadian marketplace. The Company received Notices of Allegation against Enablex® patents listed on the Canadian patent register which expire in August of 2016 and beyond.

Enablex® is currently protected in Canada by three issued patents listed on the Canadian patent register. Merus intends to vigorously defend the Enablex® intellectual property rights and pursue all available legal and regulatory pathways in defense of the product.

The Canadian net sales of Enablex® in the preceding twelve month period ended March 31, 2014 were approximately 12% of the total in-market net sales of Merus. Enablex® first received market authorization from Health Canada on November 14, 2005.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.

Cautionary Statement

Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus' actual results to be materially different from any future results expressed or implied by these statements. Such risk factors include the following: the success of any court action initiated by Merus to prevent a market authorization being issued to Apotex Inc. under the ANDS, general economic and business conditions, changes in demand for Merus' products, changes in competition, the ability of Merus to integrate acquisitions or complete future acquisitions, Merus' ability to complete any financing under its short form prospectus or otherwise, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Merus that Merus' plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.